Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v6-EN
Language English English
Date Updated 2021-09-15 2021-09-10
Drug Identification Number 02510162 02510162
Brand name XARELTO XARELTO
Common or Proper name Rivaroxaban Granules Rivaroxaban Granules
Company Name BAYER INC BAYER INC
Ingredients RIVAROXABAN RIVAROXABAN
Strength(s) 51.7MG 51.7MG
Dosage form(s) GRANULES FOR SUSPENSION GRANULES FOR SUSPENSION
Route of administration ORAL ORAL
Packaging size 100 ML 100 ML
ATC code B01AF B01AF
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2021-09-20 2021-09-20
Actual start date 2021-09-14
Estimated end date 2021-10-30 2021-10-30
Actual end date
Shortage status Actual shortage Anticipated shortage
Company comments
Health Canada comments